← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Viracyte, Llc
Cambridge, MA
$3,314,450
Total funding
2
Grants
Funding over time
peak $1.1M · FY2016–19$2M$1.5M$1M$500K$0
'16
'17
'18
'19
Funding mix
By agency
NIH$2,998,013 · 1
FDA$316,437 · 1
By mechanism
R44$2,998,013 · 1
R01$316,437 · 1
Investigators at Viracyte, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Path to Commercialization of the first âoff the shelfâ T cell product$1,022,567
R44 · FY2019 · HL
Path to Commercialization of the first âoff the shelfâ T cell product$988,677
R44 · FY2017 · HL
Path to Commercialization of the first âoff the shelfâ T cell product$986,769
R44 · FY2018 · HL
Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014)$249,863
R01 · FY2016 · FD
Phase I study of Viralym-A for the Treatment of Adenovirus disease - IND16258 (11/13/2014)$66,574
R01 · FY2018 · FD